患病类可以缓解氨基粉症病变的痴呆影响
Donald R Royall1, Raymond F Palmer2
1Department of Psychiatry, University of Texas Health Science Center.
Neuropsychology
|July 28, 2025
概括
一个算法识别了受阿米洛伊多病,痴呆症生物标志物负面影响的个体. 这种方法有助于预测生物标志物效应,并指导个性化痴呆症治疗.
科学领域:
- 神经学 神经学
- 生物标志物研究 生物标志物研究
- 阿尔茨海默病 阿尔茨海默病
背景情况:
- 痴呆症治疗正在转向以生物标志物为中心的策略.
- 生物标志物效应的变化需要精细的分析方法.
- 通过PET扫描检测到的粉样蛋白病变是与痴呆症相关的关键生物标志物.
研究的目的:
- 测试一种算法,用于识别受粉样蛋白病变不利影响的个体.
- 分析粉样蛋白负担对痴呆症严重性的影响.
- 探索一个"苦难类"在阿尔茨海默病进展中的预测价值.
主要方法:
- 利用了阿尔茨海默病神经成像计划中1,737名受试者的数据.
- 根据PET结果,将受试者分配到基于PET结果的amyloidopathy-affliction类.
- 采用了千-平方差异测试来分析缓和效应.
主要成果:
- 有阳性PET扫描的受试者中有39.3%被归类为"受苦".
- 受影响的受试者表现出更严重的痴呆症和更高的粉样蛋白负担,持续超过36个月.
- 粉样蛋白负担与痴呆症严重程度的关联因患病类别而受到缓解;患病的非痴呆个体更有可能转化为阿尔茨海默病.
结论:
- 开发的算法可以更准确地预测生物标志物效应.
- 这种方法支持针对特定痴呆症生物标志物的精确干预.
- 研究结果强调了在痴呆症护理中考虑个体对生物标志物的反应的重要性.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K
Dementia
166
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
166
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Parkinson's Disease: Overview
710
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
710


